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Enzyme variantsConsidering the key role of D-serine in N-methyl-D-aspartate receptor-mediated neurotransmission, it is
highly relevant to deﬁne the role that enzymes play in D-serine synthesis and degradation. In particular,
the details of regulation of the D-serine catabolic human enzyme D-amino acid oxidase (hDAAO) are un-
known although different lines of evidence have shown it to be involved in schizophrenia susceptibility.
Here we investigated the effect of three single nucleotide polymorphisms and known mutations in hDAAO,
i.e., D31H, R279A, and G331V. A very low amount of soluble G331V hDAAO is produced in E. coli cells: the re-
combinant variant enzyme is fully active. Human U87 glioblastoma cells transiently transfected for G331V
hDAAO show a low viability, a signiﬁcant amount of protein aggregates, and augmented apoptosis. The re-
combinant D31H and R279A hDAAO variants do not show alterations in tertiary and quaternary structures,
thermal stability, binding afﬁnity for inhibitors, and the modulator pLG72, whereas the kinetic efﬁciency
and the afﬁnity for D-serine and for FAD were higher than for the wild-type enzyme. While these effects
for the substitution at position 31 cannot be structurally explained, the R279A mutation might affect the
hDAAO FAD-binding afﬁnity by altering the “structurally ambivalent” peptide V47–L51. In agreement with
the observed increased activity, expression of D31H and R279A hDAAO variants in U87 cells produces a
higher decrease in cellular D/(D+L) serine ratio than the wild-type counterpart. In vivo, these substitutions
could affect cellular D-serine concentration and its release at synapsis and thus might be relevant for schizo-
phrenia susceptibility.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
D-Amino acid oxidase (EC 1.4.3.3, DAAO) is a peroxisomal
FAD-containing enzyme that catalyzes the oxidative deamination of
D-amino acids to their imino acid counterparts and concomitantly re-
duces FAD. The imino acid is released into solvent where it spontane-
ously hydrolyzes to the corresponding α-keto acid and ammonia; the
reduced ﬂavin is subsequently reoxidized by dioxygen, generating
H2O2 [1]. In the human brain DAAO degrades D-serine, a glutamate
coagonist that binds the “strychnine-insensitive glycine modulatory
site” on the ionotropic N-methyl-D-aspartate subtype of glutamateomazine; DAAO, D-amino acid
t protein; FAD, ﬂavin adenine
S, N-lauroylsarcosine; NMDAr,
pkDAAO, pig kidney D-amino
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e racemase (EC 5.1.1.18)
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. Pollegioni).
l rights reserved.receptors (NMDAr) which, together with the glutamate site, must
be occupied for the receptor to operate [2–6]. This site of the
NMDAr is not saturated under normal conditions [7]; thus, even
small changes in D-serine concentration may affect ionic channel
function to a signiﬁcant extent (both under physiological and patho-
logical conditions).
D-Serine is an “atypical” neuromodulator produced through the
isomerization reaction catalyzed by the PLP-dependent enzyme serine
racemase (SR, EC 5.1.1.18) from L-serine and degraded by the
α,β-elimination reaction catalyzed by the same enzyme and/or by the
oxidative deamination due to DAAO [1,6,8,9]. This signaling molecule
plays key roles in excitatory synaptic transmission and it is also involved
in a number of physiological processes related to neuronal plasticity and
in several pathological conditions [4,5,10–13]. A recentmodel of D-serine
dynamics – the so-called “serine shuttle model” [9] – proposes that as-
trocytes synthesize and export L-serine to neurons, inducing neuronal
SR to synthesize D-serine; D-serine released by neurons can be taken
up by astrocytes for storage and activity-dependent release.
Various studies have indicated that D-serine levels are decreased in
patients affected by schizophrenia [14,15]; furthermore, D-serine great-
ly ameliorated the symptoms of schizophrenia when administered
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genes linked to schizophrenia susceptibility have been discovered
[17]. Among them single nucleotide polymorphisms (SNP) and haplo-
types in the genes encoding for DAAO, pLG72, and SR have been identi-
ﬁed, reviewed in [6]. The human G72 gene encodes for pLG72, a protein
present in primates only, which interacts with human DAAO (hDAAO)
in astrocytes [18,19] and alters its stability and cellular half-life
[20,21]. We showed that newly synthesized hDAAO is transitorily pres-
ent in the cytoplasm, where it can interact with pLG72 located on the
cytosolic side of themitochondrial external membrane before being de-
livered to peroxisomes [21], and demonstrated that the cellular concen-
trations of D-serine depend on expression of the active form of this
ﬂavooxidase [19–21]. A model for correlating D-serine catabolism with
schizophrenia susceptibility was proposed: a decrease in pLG72 expres-
sion yields an anomalously high level of DAAO activity and induces an
excessive decrease in the local concentration of D-serine, see Scheme 1
[6,19]. Importantly, a similar effect can also result from mutations that
abnormally increase ﬂavoenzyme activity or affect its downregulation.
In fact, diminished DAAO activity (by expressing the inactive G181R
variant in mice) slightly enhanced D-serine levels in the brain and im-
proved behavioral deﬁcits associated with the negative and cognitive
symptoms of schizophrenia [22].
The hDAAO protomer (347 amino acids) shows the classical
αβ-structure of FAD-containing ﬂavooxidases constituted by two do-
mains: the FAD binding domain and the interface domain (Fig. 1A)
[23,24]. hDAAO differs from other known mammalian homologues be-
cause of its stable homodimeric state (also in the apoprotein form), a
weak interaction with the FAD cofactor (in the absence of an active site
ligand), and the speciﬁc interaction with pLG72 [1,19,21]. Various SNPs
of the hDAAO gene resulting in nonsynonymous substitutions have
been reported: themost well-known SNP (rs4262766, related to schizo-
phrenia susceptibility) resulted in G331V replacement. Furthermore,Scheme 1. Proposed role of hDAAO–pLG72 interaction in the modulation of D-serine availab
acts on the postsynaptic neuron as well as on the surrounding astrocytes, activating metab
catalyzed by SR). In the synaptic cleft, D-serine binds to the glycine-binding site on the NM
In glial cells pLG72 binds to hDAAO, yielding formation of a complex constituted by tw
inactivated: pLG72 modulates the amount of active hDAAO acting on the stability of the ho
Under pathological conditions, the supposed lower expression level of pLG72 would re
concentration.analysis of deposited protein sequences reveals a discrepancy at posi-
tions 31 and 279 (yielding the D31H and R279A replacements) [25]: it
is unclear at this stage whether these latter differences are due to poly-
morphisms, sequencing, or cloning artifacts. Inspection of the 3D struc-
ture of hDAAO (see Fig. 1) has shown that Arg279 is located close to
the FAD cofactor and that Asp31 and Gly331 are far from both the active
site and the interface between monomers, in a region that is likely in-
volved in the protein folding process [26].
With the ultimate goal of enhancing our understanding of the cor-
relation between enzymatic activity modulation in this ﬂavoprotein
and its possible role in schizophrenia susceptibility, we investigated
the effect of D31H, R279A, and G331V replacements on enzyme func-
tion by expressing and characterizing the corresponding single-point
hDAAO variants.
2. Materials and methods
2.1. Preparation and expression of hDAAO variants in E. coli
Mutagenesis reactions were performed using the QuickChange
site-directed mutagenesis kit (Stratagene) on the pET11b-HishDAAO
expression plasmid. Recombinant His-tagged hDAAO (wild-type and
variants) was expressed in E. coli cells and puriﬁed by HiTrap chelating
chromatography (GE Healthcare) as reported in [27]. The ﬁnal hDAAO
preparations were equilibrated in 20 mM Tris–HCl buffer, pH 8.0,
100 mM NaCl, 5% glycerol, 5 mM 2-mercaptoethanol, and 40 μM FAD
and diluted in plain buffer without FAD before use. Protein concentra-
tion of the puriﬁed enzymes was determined using the extinction coef-
ﬁcient at 455 nm (12.2 mM−1 cm−1 for wild-type hDAAO) [27].
hDAAO apoprotein was prepared by dialysis of a 2 mg protein/mL
enzyme solution vs. 50 mM sodium pyrophosphate, pH 8.3, 1 M KBr,
and 1 mM EDTA for 48 h at 4 °C. The ﬁnal apoprotein preparationility at glutamatergic synapses [6,9,19]. Glutamate released from presynaptic neurons
otropic glutamate receptors mGluR5 and synthesizing D-serine (through the reaction
DAr and in conjunction with glutamate results in the opening of the receptor channel.
o hDAAO homodimers and two pLG72 molecules. In this way complexed hDAAO is
loenzyme, thus preventing an excessive degradation of the neuromodulator D-serine.
sult in an overactivation of hDAAO and a consequent decrease in D-serine cellular
Fig. 1. Structure of human DAAO. A) Position of the residues mutated in this work (shown in color) on the structure of hDAAO (PDB code: 2E49) [24] dimer (left) and protomer
(right). B) Detail of the H-bond interaction (dashed line) between Arg279 and Pro41 (shown in yellow). Helix α2 and the VAAGL motif are shown in cyan, with the FAD cofactor
in green. An adjacent hDAAO molecule in the crystal asymmetric unit is shown in orange. Figure prepared with PyMOL (http://www.pymol.org/).
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5 mM 2-mercaptoethanol.
pLG72was prepared as stated in [28] and stored in 20 mMTris–HCl,
pH 8.5, 100 mM NaCl, 5% glycerol, and 5 mM 2-mercaptoethanol and
contained 0.1% N-lauroylsarcosine (NLS).
2.2. Activity assay
The standard assay for DAAO activity was performed by employing
an oxygen electrode at air saturation (0.253 mM O2) and 25 °C, using28 mM D-alanine as substrate in 100 mM sodium pyrophosphate
buffer, pH 8.5, containing 40 μM FAD [27]. One DAAO unit is de-
ﬁned as the amount of enzyme that converts 1 μmol of D-amino
acid per minute at 25 °C. The kinetic parameters were determined
with the same assay, employing increasing concentrations of D-ala-
nine or D-serine as substrate (0.25–50 mM for D-alanine and 0.25–
100 mM for D-serine). The initial reaction rates at different sub-
strate concentrations were used to calculate the apparent kinetic
parameters (kcat,app and Km,app) using the KaleidaGraph software
(Synergy Software).
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All spectral measurements were carried out at 15 °C. The dissoci-
ation constants for benzoate binding to hDAAO (0.4 mg protein/mL,
≈10 μM) were assessed spectrophotometrically in 20 mM Tris–HCl,
pH 8.0, 5% glycerol, and 5 mM 2-mercaptoethanol by following the
changes in absorbance at 497 nm that accompany complex formation
[27,29]. Flavin and protein ﬂuorescence were measured in a Jasco
FP-750 instrument (Cremello, Italy) at 0.1 mg/mL protein concentra-
tion in 50 mM sodium pyrophosphate, pH 8.3, and corrected for buff-
er contributions. Protein emission ﬂuorescence spectra were
recorded between 300 and 400 nm, with excitation at 280 nm; ﬂavin
emission spectra were recorded from 475 to 600 nm, with excitation
at 450 nm. FAD binding was estimated by protein ﬂuorescence
quenching at 341 nm.
Circular dichroism (CD) spectra were recorded in 20 mM Tris–
HCl, pH 8.5, 150 mM sodium chloride, and 5% glycerol, using a Jasco
J-815 spectropolarimeter, and analyzed by means of Jasco software.
The cell path length was 1 cm for measurements above 250 nm
(0.4 mg protein/mL) and 0.1 cm for measurements in the 190- to
250-nm region (0.1 mg protein/mL) [20].
Temperature-ramp experiments were performed in 20 mM Tris–
HCl, pH 8.0, 100 mM sodium chloride, 5% glycerol, and 5 mM
2-mercaptoethanol as reported previously [30]. For this a software-
driven, Peltier-equipped ﬂuorimeter was used to measure the protein
ﬂuorescence change at 340 nm or a CD spectropolarimeter to follow
the CD signal at 220 nm in order to reproduce a temperature gradient
(0.5 °C/min).
2.4. Oligomerization state and pLG72 binding
Size-exclusion chromatography was performed at room tempera-
ture on a Superdex 200 column by means of an Akta chromatographic
system (GE Healthcare), using 20 mM Tris–HCl, pH 8.5, 150 mM so-
dium chloride, 5% glycerol, and 5 mM 2-mercaptoethanol as elution
buffer. hDAAO–pLG72 complex formation and oligomeric state were
also determined by gel-permeation chromatography using the afore-
mentioned buffer, to which 0.06% NLS and 40 μM FAD were added as
the elution buffer (the detergent is required because the solubility
and the oligomeric state of pLG72 strongly depends on the presence
of NLS) [19]. The area of each peak was estimated by nonlinear
curve ﬁtting of the elution proﬁle using PeakFit software (Systat Soft-
ware, Germany). The amount of pLG72 and hDAAO present in the
peak corresponding to the protein complex (≈12.8 mL) was estimat-
ed by means of the intensity of their bands following SDS-PAGE, as
obtained using the program QuantityOne (BioRad Labs.).
2.5. Expression of hDAAO variants in U87 glioblastoma cells
The pEYFP-hDAAO-C3 construct [19,21] was used as a template
and the substitutions were introduced by the Quickchange system.
This plasmid encodes for a chimeric hDAAO fused to the enhanced
yellow ﬂuorescent protein (EYFP) located at the N-terminus of
hDAAO. The ATCC U87 human glioblastoma cells were maintained
in DMEM supplemented with 10% fetal bovine serum, 1 mM sodium
pyruvate, 2 mM L-glutamine, 1% nonessential amino acids, 1% penicil-
lin/streptomycin, and 1% amphotericin B (Euroclone) at 37 °C in a 5%
CO2 incubator as reported in [19,21]. They were then transfected
using the FuGENE HD transfection reagent (Roche) and 2 μg of the
different pEYFP-hDAAO constructs encoding for wild-type or variants
of hDAAO. Protein expression levels were monitored either by using a
ﬂuorescence microscope (Olympus IX51) equipped with an FITC ﬁlter
or by Western blot analysis. The transfected cells were used for fur-
ther experiments or to select stable clones, adding 0.4 mg/mL G418
to the growth medium [19,21]. The expression level of hDAAO was
assessed on stably transfected cells. These cells were suspended inSDS-PAGE sample buffer to reach 2500 cells/μL: 20 μL of each sample
was subjected to SDS-PAGE electrophoresis and Western blot analy-
ses. The immunoreactivity signals were detected by enhanced chemi-
luminescence (ECL Plus, GE Healthcare) using rabbit polyclonal
anti-hDAAO (1:5000, Davids Biotecnologie) or rabbit polyclonal
anti-actin (1:200, Sigma) as primary antibody [19].
Immunostaining and confocal analyses were performed as stated
in [19,21]. Brieﬂy, U87 cells were seeded on round glass coverslips
(2.5×105 cells each), incubated for 24 h at 37 °C and 5% CO2, and
transfected with pEYFP-hDAAO constructs encoding for wild-type or
variants of hDAAO. At 24 and 48 h after transfection, the coverslips
were extensively washed with PBS (10 mM dibasic sodium phos-
phate, 2 mM monobasic potassium phosphate, 137 mM NaCl, and
2.7 mM KCl, pH 7.4) and ﬁxed with 4% p-formaldehyde and 4% su-
crose in 0.1 M sodium phosphate buffer, pH 7.4, for 15 min at room
temperature. The ﬁxed cells were permeabilized and the unspeciﬁc
binding sites were blocked by incubation in PBS supplemented with
0.2% Triton X-100 and 4% horse serum. They were subsequently
stained by using primary rabbit polyclonal anti-PMP70 (peroxisomal
membrane protein 70, 1:200, Sigma) and mouse monoclonal
anti-ubiquitin antibody (F-11, 1:150, Santa Cruz Biotechnology),
followed by secondary anti-rabbit Alexa 647 and anti-mouse Alexa
546 antibodies (1:1000, Molecular Probes). Immunostained cover-
slips were imaged using an inverted laser scanning confocal micro-
scope (TCS SP5, Leica Microsystems), equipped with a 63.0×1.25
NA plan apochromate oil immersion objective. Confocal image stacks
were acquired using the Leica TCS software with a sequential mode to
avoid interference between each channel and without saturating any
pixel, as reported in [19,21].
Cellular D- and L-serine levels were determined as stated in [19,20].
Brieﬂy, 2.5×105 U87 cells stably transfected with one of the aforemen-
tioned pEYFP-hDAAO expression plasmids were suspended in 1 mL of
ice-cold 5% trichloroacetic acid, sonicated, and centrifuged for 45 min at
16,000 g. The soluble fraction was extracted with water-saturated ether,
neutralized, and derivatized with o-phthaldialdehyde/N-acetyl-L-cysteine
in borate buffer. D- and L-serine were resolved by HPLC chromatography
on a 5-μm Waters C8 (4.6×250 mm) reversed-phase column; amounts
were determined using a calibration curve obtained with standard D- and
L-serine. The analyseswere replicatedﬁve times for each condition and sta-
tistical analyses were performed using Kaleidagraph software (Synergy
Software). Variation between groups was evaluated by one-way ANOVA,
and post-hoc signiﬁcance tests were performed using Student's t
test. Signiﬁcance was assessed at pb0.05.
For Western blot analyses, U87 cells seeded in a 6-well plate
(2.5×105 cells/well) and transfected with the plasmids encoding for
wild-type or variants of hDAAO were detached by trypsin treatment at
24 and 48 h after transfection, collected by centrifugation, washed with
PBS, and sonicated in lysis buffer containing 20 mM Tris–HCl, pH 8.0,
150 mM NaCl, 0.5% NP40, 0.5% Triton X-100, 1 mM EDTA, 0.7 μg/mL
pepstatin, 1 μg/mL leupeptin, and 0.19 mg/mL PMSF. The cell lysates
were clariﬁed by centrifugation, separated by SDS-PAGE gel (20 μg of
total protein/lane), and blotted on a PVDF membrane. The expression
level of the different EYFP-hDAAO variants was detected by using rabbit
polyclonal anti-hDAAOantibodies (1:3000, Davids Biotecnologie) and an
HRP-conjugated anti-rabbit secondary antibody (1:15000, Jackson
ImmunoResearch). Detection of α-actin using a rabbit polyclonal
anti-α-actin antibody (1:1000, Sigma) was used as loading control.
Blots were developed using the ECL Prime kit (GE Healthcare). Densito-
metric analysis of the immunorecognized bands was performed using
the Quantity One software (Biorad): each hDAAO-quantiﬁed signal was
normalized by the corresponding α-actin signal.
2.6. Caspase-Glo 3/7 assay
U87 cells were seeded in 96-well plates at a density of 104 cells/
well, incubated for 24 h at 37 °C and 5% CO2, and transfected using
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pEYFP-hDAAO wild-type, pEYFP-hDAAO-G331V, or pEYFP constructs.
After 24 or 48 h of incubation at 37 °C and 5% CO2, caspase-3 and
caspase-7 activity in the transfected cells was measured using the
Caspase-Glo 3/7 Assay kit (Promega). According to the manufacturer's
instructions, 100 μL of the Caspase-GloW 3/7 reagent was added to
each well and the cells were incubated for 2 h at 25 °C. The light emis-
sion – produced by caspase substrate cleavage, aminoluciferin release,
and the subsequent luciferase reaction – was measured by a plate
reader (Inﬁnite 200, Tecan). The suggested controls were analyzed in
parallel.3. Results
3.1. Expression of hDAAO variants in E. coli
The D31H and R279A variants of hDAAO were efﬁciently
overexpressed as soluble proteins in BL21(DE3) Star E. coli cells
(≈20 and 10 mg/L of fermentation broth, respectively) using the
same conditions set up for the wild-type ﬂavoenzyme [27]. In con-
trast, under these conditions the G331V hDAAO variant was
expressed as inclusion bodies. This hDAAO variant was obtained in
soluble form only by using the E. coli Origami (DE3) cells as host, a
K-12 derivative strain with mutations in both the thioredoxin reduc-
tase and glutathione reductase genes and which greatly enhances di-
sulﬁde bond formation in the cytoplasm and expression of active
proteins. Nonetheless, G331V hDAAO expression level was too low
for a detailed biochemical characterization (b0.1 mg/L of fermenta-
tion broth). In order to increase its expression, a simpliﬁed factorial
design approach was employed [31] by investigating the growth me-
dium (LB or TB), the OD600nm at the moment of inducer addition (0.8–
3.8), the time of cell collection (0, 3, 5, 20 h), and a lower temperature
of growth (25 or 30 °C) after adding IPTG. No signiﬁcant increase in
the expression of soluble and active G331V hDAAO variant was
reached. Analogously, no improvement in enzyme variant recovery
was observed by adding 1 mM benzoate (a competitive hDAAO inhib-
itor, see below) during the puriﬁcation procedure. Indeed, Western
blot analysis of recombinant E. coli whole cells (resuspended in
SDS-PAGE sample buffer) excluded proteolytic processing of the
expressed hDAAO variant (not shown). The speciﬁc activity of the par-
tially puriﬁed G331V hDAAO variant obtained by HiTrap chelating
chromatography (≈25% purity) was 2.9 U/mg protein (corresponding
to 11.6 U/mg protein for the pure enzyme variant vs. 12 U/mg protein
for the wild-type one). Taken together, these results indicate that
G331V substitution signiﬁcantly affects the expression of a soluble
form of hDAAO but does not inﬂuence its enzymatic competence.
Recombinant D31H and R279A hDAAO variants were puriﬁed by
a single chromatographic step on the HiTrap chelating column with
a ≥60% recovery and a ≥90% purity, as judged by SDS-PAGE. The
speciﬁc activity was 10.5 and 14.0 U/mg protein for R279A and
D31H variants vs. 12 U/mg protein for the wild-type hDAAO, see
Table 1 [27].Table 1
Comparison of the apparent kinetic parameters of wild-type and variants of hDAAO. The ac
Enzyme Speciﬁc activitya kcat (s−1)
(U/mg protein) D-serine D-alanine
Wild-type 12.0 3.0±0.1 5.2±0.1
D31H 14.0 3.0±0.2 6.0±0.2
R279A 10.5 2.5±0.1 8.6±0.1
G331V 2.9 (≈11.6)b n.d. n.d.
n.d.=not determined.
a Speciﬁc activity was determined using the oxygen-consumption assay at 28 mM D-alan
b Value estimated based on a ≈25% purity (see text for details).3.2. Biochemical properties of expressed hDAAO variants
The visible absorption spectrum of puriﬁed D31H and R279A vari-
ants in the oxidized state did not signiﬁcantly differ from that of the
wild-type hDAAO holoenzyme (Fig. 2A), nor did the near- and
far-UV CD spectra (not shown). These results indicate that the substi-
tutions at position 31 and 279 did not alter the overall (secondary and
tertiary) protein conformation of hDAAO or the microenvironment
surrounding the ﬂavin cofactor.
The temperature sensitivity of speciﬁc features of the holo- and
apoprotein forms of wild-type, D31H, and R279A hDAAOs was com-
pared using temperature-ramp experiments. By following changes
in tryptophan ﬂuorescence (taken as reporter of tertiary structure
modiﬁcation) and in CD signal at 220 nm (as reporter of the change
in secondary structure) midpoint transition temperatures were
obtained that were marginally higher for the D31H in the holoen-
zyme form and for the apoprotein of R279A variant than for the
wild-type hDAAO (Suppl. Table 1).
The apparent kinetic parameters of hDAAO variants were deter-
mined using the oxygen-consumption assay at ﬁxed 21% oxygen sat-
uration and in the presence of 40 μM FAD in the assay mixture [27].
The Km for the physiological substrate D-serine for D31H and R279A
hDAAO variants was 2-fold lower with respect to the wild-type en-
zyme, whereas the kcat value was similar (Table 1). In contrast, an in-
crease in apparent kcat was evident on D-alanine while the Km was
unchanged. Interestingly, the kinetic efﬁciency is higher for both var-
iants and on both the D-amino acids used than for wild-type hDAAO.
Concerning inhibitor binding, the D31H and R279A hDAAO variants
did not show signiﬁcant alterations in binding afﬁnity for benzoate – a
substrate-competitive inhibitor that binds to the oxidized hDAAOholoen-
zyme and yields a shoulder at 493 nm in the visible absorption spectrum
of the holoenzyme, see Fig. 2B [27] – as compared to wild-type hDAAO,
see Table 2. Similarly, chlorpromazine (CPZ), an FAD-competitive inhibi-
tor and a drug widely employed for the treatment of schizophrenia
[19,20], did not show alterations in binding afﬁnity either.
In solution, wild-type hDAAO exists as an equilibrium of holo- and
apoprotein forms because of the low afﬁnity for the FAD cofactor
(Kd=8 μM) [27]. Analogously to the wild-type enzyme, the apoprotein
form of both D31H and R279A hDAAOs was obtained by dialysis vs. a
chaotropic salt (1 M KBr): for both variants, the apoprotein maintained
the secondary structure of the holoenzymewhile the CD band centered
at ≈270 nm, corresponding to the tertiary structure, was lost (not
shown). These properties resemble those of wild-type hDAAO [27,30].
The Kd for cofactor binding to the apoprotein of the D31H and R279A
hDAAO variants was determined by following the change in protein
ﬂuorescence intensity at increasing FAD concentrations (Fig. 2C). Im-
portantly, both enzyme variants showed a higher afﬁnity for the FAD
cofactor than thewild-typehDAAO(up to 10-fold for the R279Avariant,
Table 2). Indeed,when thewild-type and hDAAO variantswere saturat-
ed by benzoate (1 mM) a ≈15- to 30-fold increase in afﬁnity for FAD
was observed (Table 2): even in the benzoate-complex form, the
D31H and R279A variants again interacted more tightly with the cofac-
tor than the wild-type hDAAO.tivity was assayed at air saturation (0.25 mM oxygen), 25 °C and pH 8.5.
Km (mM) kcat/Km (s−1 mM−1)
D-serine D-alanine D-serine D-alanine
7.5±0.5 1.1±0.2 0.40 4.7
3.9±0.9 0.95±0.10 0.77 6.3
3.4±0.5 1.0±0.1 0.74 8.6
n.d. n.d. n.d. n.d.
ine and in the presence of 40 μM FAD [27].
Table 2
Comparison of binding afﬁnity (Kd) for benzoate, CPZ and FAD of wild-type and vari-
ants of hDAAO.
Benzoate (μM) CPZ (μM) FAD (μM)a
Free form Benzoate complex
Wild-type 7.0±2.0 5.0±0.1 8.0±2.0 0.3±0.1
D31H 4.6±0.4 4.8±0.3 1.8±0.1 0.13±0.02
R279A 8.0±0.5 6.4±0.3 0.9±0.1 0.030±0.002
Experiments were performed in 20 mM Tris–HCl, pH 8.0, containing 5% glycerol, and
5 mM 2-mercaptoethanol at 15 °C.
a In 50 mM sodium pyrophosphate buffer, pH 8.3.
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loenzyme form retained the dimeric oligomerization state, as judged by
gel-permeation chromatography. Furthermore, the samemethodwaspre-
viously used to investigate the interaction of wild-type hDAAO with its
physiological binding partner pLG72, yielding a 200-kDa complex com-
posed of two hDAAO homodimers and two pLG72 monomers [19]. For
the hDAAO–pLG72 complex formation a Kd in the 1–5×10−7 M range
was determined [20]. Gel-permeation analysis demonstrated that the abil-
ity to interactwithpLG72wasmaintained for bothhDAAOvariants (Suppl.
Fig. 1). The analysis of the saturation of the area of the peak at 12.8 mL at
increasing pLG72 concentrations (inset of Suppl. Fig. 1A, B) according to
the Stinson's method [29] estimated a Kd of≈10−7 M, thus demonstrat-
ing that the D31H and R279A substitutions did not affect the strength of
hDAAO–pLG72 complex formation.
3.3. Structural considerations of expressed hDAAO variants
Asp31, the ﬁrst residue of strand β2, is located far from both the
substrate and the FAD binding sites (Fig. 1A). Therefore, the effects
of D31H substitution can be explained at a structural level, assuming
only a general, long-range interaction that affects protein conforma-
tion and propagates from the mutation site to the hDAAO interior.
In the case of the R279A substitution, in contrast, the absence of the
guanidyl group can be predicted to have a direct role in hDAAO–
FAD interaction. Arg279 is located in strand β12, which on one side
contacts the FAD binding site at the isoalloxazine ring and on the
other contributes to the interface between two dimers in the
hDAAO crystals (Fig. 1B). The failure of any attempt to crystallize
the hDAAO R279A protein suggests that structural alterations may
occur in the mutation site's surroundings, thus inﬂuencing (directly
or indirectly) both the crystal contact region and the FAD binding
pocket. Indeed, strand β12 contacts the α2 region containing the hy-
drophobic stretch (residues 47–51: VAAGL), which covers the si-face
of the ﬂavin ring, and analysis of different hDAAO structures shows
that in several cases (PDB codes 2E4A, 2E49, 3CUK, and 3G3E)
Arg279 is directly involved in H-bonding of the carbonyl oxygen of
Pro41 (immediately preceding theα2 helix) (Fig. 1B). This hydropho-
bic stretch has been proposed to play an important role in determin-
ing the afﬁnity for FAD and to be a structurally ambivalent peptide
(SAP) [24] since it can assume different conformations, depending
on the local and/or global context of the protein. In particular, this hy-
drophobic stretch is structurally different in hDAAO and porcine
DAAO (pkDAAO, where a structural transition occurs between the re-
duced and oxidized forms), while maintaining the same sequence,
also in the ﬂanking regions (residues 43–55). Thus, the weaker
FAD binding and the slower rate of ﬂavin reduction in hDAAO, as
compared to pkDAAO, was correlated to hDAAO in the global context.
Here, the VAAGL stretch is restricted to a single conformation withFig. 2. Spectral properties of wild-type and variants of hDAAO. A) Visible absorbance spec-
trum of wild-type (———), D31H (∙∙∙∙) and R279A (− − −) hDAAOs in the oxidized state,
at 15 °C. B) Effect of benzoate binding to oxidized D31H (∙∙∙∙) and R279A (−−−) variants
of hDAAOs: 0.28 mM benzoate was added to 10 μM of hDAAO at pH 8.0 and 15 °C.
C) Changes in ﬂuorescence signal at 341 nm following the titration of 1 μM apoprotein of
wild-type, D31H- or R279A-hDAAOwith increasing FAD concentrations, at pH 8.3 and15 °C.
Fig. 3. Time course of subcellular distribution upon transient transfection in U87 cells for wild-type, D31H, and R279A EYFP-hDAAO variants. U87 cells transiently transfected with EYFP-hDAAO, EYFP-hDAAO-D31H, or EYFP-hDAAO-R279A
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backbone N atom of Ala49, present instead in the oxidized pkDAAO
(3.0 Å) and partly weakened in the reduced form (3.3 Å) [24,32].
Based on this evidence, it is tempting to propose that the R279A mu-
tation alters the structure of the hDAAO SAP region (directly through
the loss of the H-bond to Pro41, or indirectly through a general
rearrangement of the β12–α2 interface region) (Fig. 1B), and conse-
quently the FAD binding afﬁnity in the hDAAO R279A variant (Kd=
0.9 μM) relative to the wild-type enzyme (Kd=8.0 μM, Table 2). In
this context, the SAP region and the FAD binding properties of
R279A hDAAO would be more similar to those of pkDAAO (Kd=
0.2 μM) where a tyrosine is present at position 279 and H-bonding
does not form with Pro41 [33].
3.4. Subcellular localization of EYFP-hDAAO variants and their effect on
D-serine level in transfected U87 cells
The physiological effect of the investigated substitutions in hDAAO
was studied on U87 human glioblastoma cells stably expressing D31H
or R279A EYFP-hDAAOvariants by assessing the subcellular localizationFig. 4. Time course of G331V EYFP-hDAAO variant subcellular distribution upon transient
transfected with the wild-type chimeric ﬂavoprotein or with the G331V variant (yellow)
and ubiquitin signal (red) patterns. At 24 h after transfection, the wild-type EYFP-hDAAO p
iant chimeric protein displayed a heterogeneous distribution. In≈40% of the G331V EYFP-h
two-thirds of them EYFP ﬂuorescence was partially diffused in the cytoplasm and also conce
In the remaining cells, an increased intensity of ubiquitin signal and an increased signal siz
overlapped (panel 2). At 48 h from transfection, the wild-type EYFP-hDAAO (panels on the
the cells expressing G331V EYFP-hDAAO the presence of large and dense protein aggregates
phology (panel 1), even though the peroxisomal marker distribution indicated an altered or
and large and compact signals corresponding to PMP70 and ubiquitin, suggesting that the ce
spots) was observed. EYFP=yellow channel; PMP70=blue channel; ubiquitin=red channof the ﬂavoenzyme variants and bymeasuring cellular D-serine concen-
trations. The subcellular distribution of D31H and R279A EYFP-hDAAO
variants in transiently transfectedU87 human glioblastoma cells closely
resembles that observed forwild-type hDAAO: these variants largely lo-
calize to peroxisomes (Fig. 3). The time course of compartmentalization
for wild-type and D31H EYFP-hDAAOs shows that the signal is mainly
cytosolic (70–90%) at 24 h from transfection and largely compartmen-
talized (70–85%) to peroxisomes at 48–72 h, as indicated by the overlap
with the signal for PMP70, a marker of peroxisomes; see also [21]. A
similar behavior was observed for the R279A hDAAO variant, the only
exception being that a comparatively higher amount of diffused signal
was apparent at 48 h (≈50% vs. 15–30% forwild-type or D31H variant).
In contrast, a more complex situation was apparent for U87 cells tran-
siently expressing the EYFP-hDAAO-G331V (Fig. 4). In this case protein
localization with respect to ubiquitin was also investigated since a pro-
nounced propensity of the variant hDAAO to form dense aggregates
within the cells, altering cell viability, was observed. At 24 h from trans-
fection, when the majority of cells expressing wild-type EYFP-hDAAO
(≈73%) show a largely cytosolic EYFP signal distinct from the one asso-
ciated with the peroxisomal marker PMP70, ubiquitin signal patterntransfection in U87 cells. The cellular distribution of EYFP-hDAAO signal in the cells
was monitored by confocal analyses and compared with PMP70 (peroxisomes, blue)
rotein (panels on the left) showed the expected, largely cytosolic signal, while the var-
DAAO transfected cells, the formation of aggregates of different sizes was observed: for
ntrated in small aggregates which did not colocalize with PMP70 or ubiquitin (panel 1).
e for G331V EYFP-hDAAO was apparent; PMP70, ubiquitin, and EYFP signals partially
left) showed a partially compartmentalized pattern, while for a large part (≈80%) of
through the cells is evident. Half of these cells conserved a nearly normal cellular mor-
ganization of this cellular compartment; the rest of the cells showed a spherical shape
lls were not viable (panel 2). In both cases an extensive colocalization of signals (white
el. Bar=10 μm.
Fig. 5. Caspase activity detection (panel A) in U87-transfected cells expressing wild-type
and G331V EYFP-hDAAOs (panel B). A) Caspase activity was assayed at 24 and 48 h after
transient transfection ofwild-type or G331V EYFP-hDAAO and compared to that detected
in control cells (nontransfected or EYFP-transfected U87 cells). The protease activity was
measured as relative light units (RLU) by lysing the cells in the presence of Caspase-Glo 3/
7 substrate. A signiﬁcant increase in the detected valueswas observed in the cells express-
ing the G331V EYFP-hDAAO at 48 h after transfection. Black bars=wild-type
EYFP-hDAAO transfected cells; white bars=G331V EYFP-hDAAO-transfected cells; dark
gray bars=EYFP-transfected cells; light gray bars=nontransfected U87 cells. The values
are reported as the mean±standard deviation. *p=0.001. B) Western blot analysis of
samples used in panel A; 20 μg of total proteins were loaded in each lane.
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U87 cells. On the other hand, ≈45% of cells expressing the
EYFP-hDAAO-G331V show a cytosolic, diffused ﬂuorescent signal
for hDAAO (similar to that observed for wild-type hDAAO), 42% of
cells forming cytosolic protein aggregates and the remaining cells
seemingly nonviable. In≈70% of cells displaying EYFP-hDAAO-G331V
aggregates, the EYFP signal does not overlapwith the signal for the per-
oxisomal marker PMP70 (panel 1 at 24 h, Fig. 4), whereas in the
remaining cells a partial superimposition of the signal corresponding
to EYFP, PMP70, and ubiquitin is evident (white regions in merge
panel 2 at 24 h, Fig. 4). At 48 h from transfection, the cells expressing
wild-type EYFP-hDAAO show a punctuate distribution pattern for the
ﬂavoenzyme largely overlapping with the signal for PMP70 (Fig. 4,
panel at 48 h). In transfected cells, ubiquitin signal intensity is signiﬁ-
cantly higher than in nontransfected ones and colocalizes with that of
EYFP-hDAAO variant aggregates. On the other hand, large – 0.5 μm or
greater in diameter – protein aggregates are present in most of the
cells expressing the EYFP-hDAAO-G331V. In≈50% of these transfected
cells, the aggregates partially overlap with PMP70 signal distribution
(panel 1 at 48 h, Fig. 4): importantly, peroxisomes assume an altered
(fused)morphology in the same cells. The remaining 50% of transfected
cells show, in addition, an abnormal cellmorphology (round shape) and
alteration of peroxisome morphology: an extended colocalization of
G331V hDAAO, PMP70, and ubiquitin signals is apparent (white regions
in merge panel 2 at 48 h, Fig. 4).
The protein aggregation due to the expression of the G331V hDAAO
variant affects cell viability. To investigate whether the caspase 3/7 path-
way is involved in inducing apoptosis, a Caspase-Glo 3/7 assay was
performed on U87-transfected cells. At 24 h from transient transfection,
caspase activity is similar between control (nontransfected or transfected
with the pEYFP plasmid) cells and the ones expressing wild-type or
G331V hDAAO variants, while at 48 h a statistically signiﬁcant increase
in caspase activity in cells expressing the G331V hDAAO is apparent
(Fig. 5A). This change is all the more conspicuous considering that at
48 h the level of G331V hDAAO is signiﬁcantly lower (≈10-fold) than
for the wild-type counterpart (Fig. 5B). This result is not due to differ-
ences in transfection yieldswith different constructs because no variation
in this parameter was observed by using the NanoLuc luciferase as a ge-
netic reporter (Nano-Glo Luciferase Assay System, Promega).
U87 glioblastoma clones stably expressing EYFP-hDAAO-D31H or
-R279A proteins were isolated based on the ﬂuorescence signal of
EYFP and then conﬁrmed by Western blot and DAAO activity analyses
(Fig. 6). The expression level for D31H variant resembled that of
wild-type hDAAO, while a ≈30% higher expression was apparent for
the R279A variant. On the other hand, it was not feasible to select stable
clones expressing the G331V hDAAO variant because this affected cell
viability (see also above): no viable cells were found 7 days after trans-
fection. The cellular concentration of D- and L-serine in U87 stably
transfected cells was assessed by HPLC chromatography [19,30].
EYFP-hDAAO-D31H and -R279A protein expression was associated
with a statistically signiﬁcantly higher decrease in cellular D/(D+L)
serine ratio than for the wild-type hDAAO in stably transfected U87
human glioblastoma cells (Fig. 7).
4. Discussion
4.1. G331V substitution
The in vitro and cellular experiments reported in the present study
demonstrate that substitution of Gly331 with valine (SNP rs4262766)
altered the solubility of hDAAOwhile the speciﬁc activity of this enzyme
variant did not differ from that of the wild-type counterpart. Gly331 is
located on the C-terminal α-helix (Fig. 1): substituting it by a valine
might affect the helix structure and produce a hydrophobic surface
that promotes protein aggregation in the folded protein or during the
folding process since C-terminal α-helix is exposed in the foldingintermediate(s) of yeast DAAO [26]. Accordingly, only a very low
level of soluble G331V hDAAO was obtained in E. coli cells
(≤0.1 mg/L of fermentation broth), and human U87 glioblastoma
cells stably expressing this hDAAO variant were not maintained in
culture because of a low viability, while transiently transfected U87
cells showed a signiﬁcant increase in aggregate-containing cells. Indeed,
the G331V hDAAO variant is not efﬁciently targeted to peroxisomes and
because of its ability to oxidize cytosolic D-serine – and produce hydro-
gen peroxide – it might be cytotoxic. Both the low solubility and the cy-
tosolic activity of G331V hDAAO could be responsible for this low
viability of U87 transfected cells, as suggested by the increase in caspase
activity at 48 h from transfection. Importantly, even the R199W hDAAO
substitution associated with classical adult-onset familial amyotrophic
lateral sclerosis reduced cell viability: cells expressing this DAAO variant
showed abnormal shape features and the presence of ubiquitinated pro-
tein aggregates [34]. It was suggested that protein aggregation (inmotor
neurons) might play a main role in initiating disease in familial cases.
4.2. D31H and R279A substitutions
Thermal stability, binding afﬁnity for inhibitors (benzoate and
chlorpromazine), dimeric oligomerization, and interaction with the
binding partner pLG72 were not altered signiﬁcantly in the D31H
Fig. 6. A) Confocal analysis of the subcellular localization of EYFP-hDAAO-D31H and -R279A variants in stably transfected U87 human glioblastoma cells. The distribution of the
yellow ﬂuorescent fusion protein (EYFP-hDAAO) is merged with the distribution of the peroxisomal marker PMP70 (red channel). Scale bars=5 μm. B) Western blot analysis
performed using rabbit anti-hDAAO antibodies conﬁrms expression of EYFP-hDAAO wild-type, -D31H, or -R279A variants in stably transfected U87 cells (top panel). The same
amount of sample (5×104 cells) was loaded in each lane, as conﬁrmed by using an anti-α-actin antibody as internal control (bottom panel). C) DAAO activity in U87 cells stably
transfected with EYFP-hDAAO wild-type, -D31H, or -R279A variants determined by Amplex UltraRed assay. The values are expressed as a percentage, taking as 100% the DAAO
activity in U87 cells stably transfected with EYFP-hDAAO wild-type.
Fig. 7. Comparison of D/(D+L) serine ratio (%) in U87 cells not transfected (3.86±0.54%,
means±S.E.) and stably transfected with EYFP-hDAAO wild-type (1.29±0.28%), -D31H
(1.01±0.27%) or -R279A variants (0.92±0.21%). The change in D/(D+L) serine ratio
with respect to theU87 cells stably transfectedwithwild-type EYFP-hDAAO is statistically
signiﬁcant for U87-EYFP-hDAAO-D31H (*p=0.014) and for U87-EYFP-hDAAO-R279A
(**p=0.0008).
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ﬁnity for both the physiological substrate D-serine and the FAD cofac-
tor were higher than for the wild-type enzyme (Tables 1, 2). While
these effects for the substitution at position 31 can be rationalized
from a structural point of view in terms of general, long-range inter-
actions that affect protein conformation, we suggest that the R279A
mutation might affect the FAD binding afﬁnity in hDAAO by altering
the structure of the hDAAO SAP region directly through the loss of
the H-bond to Pro41, or indirectly through a general rearrangement
of the β12–α2 interface region.
In U87-transfected cells both D31H and R279A hDAAO variants
are delivered to peroxisomes (as they colocalize with the peroxisomal
marker PMP70) in both transiently and stably transfected cells. More-
over, the expression of EYFP-hDAAO-D31H and -R279A proteins pro-
duced a higher decrease in the cellular D/(D+L) serine ratio than the
wild-type hDAAO in the same U87 cells. These results suggest that
D31H and R279A hDAAO variants more efﬁciently oxidize D-serine
(as compared to the wild-type counterpart) and their expression
could affect cellular D-serine concentrations and its release at synapsis:
this evidence substantiate DAAO's role in the onset of schizophrenia. In
fact, the use of DAAO inhibitors as well as the expression of a hypo-
functional DAAO in animal models [35,36], produced modest increases
410 L. Caldinelli et al. / Biochimica et Biophysica Acta 1832 (2013) 400–410in brain D-serine levels but successfully reversed behavioral deﬁcits in-
duced by NMDAr antagonism. Our evidence supports the hypothesis
that moderate increases in hDAAO activity can affect the neurotrans-
mitter level and mediate schizophrenia susceptibility.
5. Conclusions
In order to elucidate the role of D-serine in NMDAr-mediated neuro-
transmission, the function of the enzymes involved in D-serine synthe-
sis and degradation needs to be deﬁned. While modulation of SR
activity by post-transcriptional modiﬁcations and binding partners is
well established [6,8], less is known about the D-serine catabolic en-
zyme hDAAO. Up to now, hDAAO variants directly related to schizo-
phrenia have not been identiﬁed: for this reason it is of great
importance to biochemically characterize the hDAAO variants that are
reported in protein or SNP databases. From the disease pathological
standpoint, it is also of utmost importance to elucidate reported substi-
tutions on hDAAO function in order to validate the hypothesis that a
hypofunction of NMDAr due to D-serine depletion – as the result of an
excess of hDAAO activity – enhances schizophrenia susceptibility.
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